Deciphera Pharmaceuticals, Inc. Accounts Receivable
Deciphera Pharmaceuticals, Inc. had Accounts Receivable of $32.68 million as of 2024-03-31, per its 10-Q filed 2024-05-10.
Discontinued › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2024-05-10
- 2024-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $32.68M.
- 2023-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $31.95M.
- 2023-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $27.55M.
- 2023-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $23.20M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2024-03-31 | $32.68M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $31.95M 10-Q · filed 2024-05-10 |
| 2023-09-30 | $27.55M 10-Q · filed 2023-10-30 |
| 2023-06-30 | $23.20M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $22.44M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $22.43M 10-K · filed 2024-02-07 |
| 2022-09-30 | $23.28M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $25.85M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $23.15M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $20.59M 10-K · filed 2023-02-07 |
| 2021-09-30 | $18.05M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $18.61M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $21.82M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $13.90M 10-K · filed 2022-02-08 |
| 2020-09-30 | $11.81M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $7.38M 10-Q · filed 2020-08-04 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-09 |
| 2019-06-30 | $20.00M 10-Q · filed 2019-08-02 |